The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

The Dundee spinout has raised more than $304m in its IPO in the US, with another $160m secured through a concurrent private placement.

Based on research at Deakin University, Li-S Energy has gone public on the Australian Stock Exchange after raising $25m in its initial public offering.

Case Western Reserve University-linked Lucid Diagnostics is seeking an initial public offering that would net it up to $57.5m.

Oracle has signed up to be a cornerstone investor for Oxford Nanopore’s initial public offering, putting up half of the $410m target.

Genetic testing services provider Prenetics, a spinout of City University of Hong Kong, will hold a reverse merger at a $1.25bn valuation.

Based on research at Drexel University, Context Therapeutics is seeking to raise up to $21m in an initial public offering on Nasdaq.

Dundee spinout Exscientia is continuing a busy fundraising year with a filing for an IPO in the US and a $35m concurrent private placement.